Nutritional considerations with antiobesity medications

Author:

Almandoz Jaime P.1ORCID,Wadden Thomas A.2ORCID,Tewksbury Colleen3,Apovian Caroline M.4ORCID,Fitch Angela5,Ard Jamy D.6ORCID,Li Zhaoping7ORCID,Richards Jesse8ORCID,Butsch W. Scott9ORCID,Jouravskaya Irina10,Vanderman Kadie S.11ORCID,Neff Lisa M.10ORCID

Affiliation:

1. Division of Endocrinology University of Texas, Southwestern Medical Center Dallas Texas USA

2. Department of Psychiatry University of Pennsylvania Philadelphia Pennsylvania USA

3. Department of Surgery University of Pennsylvania Philadelphia Pennsylvania USA

4. Division of Endocrinology, Diabetes and Hypertension Brigham and Women's Hospital Boston Massachusetts USA

5. Knownwell Boston Massachusetts USA

6. Department of Epidemiology and Prevention and Department of Medicine Wake Forest School of Medicine Winston‐Salem North Carolina USA

7. Center for Human Nutrition University of California Los Angeles Los Angeles California USA

8. Department of Internal Medicine University of Oklahoma School of Medicine Tulsa Oklahoma USA

9. Bariatric and Metabolic Institute Cleveland Clinic Cleveland Ohio USA

10. Eli Lilly and Company Indianapolis Indiana USA

11. Syneos Health Morrisville North Carolina USA

Abstract

AbstractThe improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence‐based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well‐being and promote optimal nutritional and medical outcomes.

Funder

Eli Lilly and Company

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3